3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Gastrointestinal Stromal Tumors
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Burkitt Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Melanoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia, Biphenotypic, Acute
1
Hypereosinophilic Syndrome
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Digestive System Neoplasms
1
Congenital Bone Marrow Failure Syndromes
1
Blast Crisis
1
Interventions
fludarabine
2
durvalumab
2
Cyclophosphamide
2
ruxolitinib
1
repotrectinib
1
ponatinib
1
pembrolizumab
1
gilteritinib
1
fludarabine phosphate
1
cemiplimab
1
atezolizumab
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Immunotherapy
1
Idarubicin
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Cytarabine
1
Cisplatin
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Imatinib Mesylate
×
90 days
×
Clear all
No trials found.